Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis

Journal of Managed Care Pharmacy

Volumn 17, Issue 5, 2011, Pages 377-381

  Becker, Russell III V ^a   Dembek, Carole ^b  

^a Russell Becker Consulting   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO; BETA INTERFERON; IMMUNOLOGIC FACTOR; PEPTIDE;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; MODEL; MULTIPLE SCLEROSIS; RELAPSE; SENSITIVITY ANALYSIS; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; ECONOMICS; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; PATIENT; PATIENT SELECTION; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MODELS, ECONOMIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT DROPOUTS; PATIENT SELECTION; PEPTIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052537399     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.5.377     Document Type: Article

References (23)

1. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9-17. Available at: http://www.ispor.org/workpaper/healthscience/TFModeling.pdf. Accessed May 27, 2011.
2. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-71.
3. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed May 27, 2011.
4. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002;5(1):44-54.
5. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326(7388):522. Available at: http://www.bmj.com/content/326/7388/522.full.pdf. Accessed May 27, 2011.
6. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7(5):554-68.
7. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-61. Available at: http://www.amcp.org/data/jmcp/245-61.pdf.
8. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Costeffectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617-27.
9. Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of diseasemodifying therapies in the management of multiple sclerosis for the Medicare population. Value Health. 2009;12(5):657-65.
10. Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin. 2009;25(6):1445-54.
11. Nuijten M, Mittendorf T. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther. 2010;32(4):717-28.
12. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15(7):543-55. Available at: http://www.amcp.org/data/jmcp/543-555.pdf.
13. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703-12. Available at: http://www.amcp.org/data/jmcp/703-712.pdf.
14. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17. Available at: http://www.biomedcentral.com/content/pdf/1472-6963-3-17.pdf. Accessed May 24, 2011.
15. Hakim Z. Using decision-analytic models wisely. J Manag Care Pharm. 2003;9(5):449-50. Available at: http://www.amcp.org/data/jmcp/Editorial-449-450.pdf.
16. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-94.
17. No authors listed. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. The IFNβ Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61.
18. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
19. No authors listed. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45(7):1277-85.
20. No authors listed. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-504.
21. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628-36.
22. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-60.
23. Panitch H, Goodin D, Francis G et al. Benefits of high-dose, highfrequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239(1):67-74.